Some people taking GLP-1 or related medicines notice changes in appetite, reward, energy, sleep, or mood. Others notice no mood change or feel better as glucose, weight, or routines improve.
Quick summary
The cautious message is balanced: regulators reviewed reports of suicidal thoughts or actions and did not find evidence of a causal link, but new or worsening mental health symptoms should still be taken seriously.
Key takeaways
- Do not ignore persistent depression, anxiety, emotional numbness, or suicidal thoughts.
- Do not stop diabetes or weight medicine abruptly without medical advice unless emergency instructions apply.
- Mood changes may also relate to low intake, dehydration, sleep, alcohol, life stress, or other medicines.
- People with a mental health history should discuss monitoring before and after medicine changes.
What to track
- When the mood change started.
- Dose changes or missed meals.
- Sleep, nausea, vomiting, dehydration, or low intake.
- Alcohol or substance use.
- Any thoughts of self-harm or not wanting to live.
What to do
Contact the prescribing clinician for persistent or worrying mood changes. Ask whether the timing suggests medicine intolerance, nutrition problems, sleep disruption, another medical issue, or an unrelated mental health condition.
If suicidal thoughts or immediate danger occur, use crisis or emergency support now rather than waiting for a routine appointment.
Practical takeaway
Mood symptoms deserve care even when a medicine link is uncertain. Safety comes first.
Safety note
This article is not a substitute for medical care. If you may harm yourself or someone else, call emergency services now. In the United States, call or text 988 for crisis support.
What to ask your care team
- Could my symptoms relate to the medication, low intake, or another cause?
- Should we adjust treatment or add mental health support?
- What crisis plan should I use if symptoms worsen?
Related reading
Source summary
- FDA Evaluation of GLP-1 Medicines and Suicidal Thoughts or Actions, U.S. Food and Drug Administration. Drug safety communication. Accessed June 5, 2026. Source
- EMA PRAC Review of GLP-1 Receptor Agonists and Suicidal Thoughts, European Medicines Agency. Regulatory safety update. Accessed June 5, 2026. Source
- Diabetes and Mental Health, Centers for Disease Control and Prevention. Patient guidance. Accessed June 5, 2026. Source
- 988 Suicide and Crisis Lifeline, 988 Lifeline. Crisis resource. Accessed June 5, 2026. Source